Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine

Luisa Rossi; Rosanna Squitti; Patrizio Pasqualetti; Eliana Marchese; Emanuele Cassetta; Elisabetta Forastiere; Giuseppe Rotilio; Paolo M. Rossini; Alessandro Finazzi-Agró

doi:10.1016/S0304-3940(02)00599-2

Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine

Luisa Rossi, Rosanna Squitti, Patrizio Pasqualetti, Eliana Marchese, Emanuele Cassetta, Elisabetta Forastiere, Giuseppe Rotilio, Paolo M. Rossini, Alessandro Finazzi-Agró

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Abstract

Copper, zinc superoxide dismutase (Cu, Zn SOD) activity was measured in red blood cells (RBC) of 32 patients affected by Alzheimer's disease (AD), eight other AD patients treated with the copper-chelating agent D-penicillamine, 13 first-degree relatives and 22 controls. All AD patients enrolled in our study showed a higher level of Cu, Zn SOD activity early in the disease. No correlation between apolipoprotein E genotype and SOD activity was found in AD patients. D-penicillamine treatment of AD patients for 24 weeks lowered the enzyme activity even below the control value. These results support the hypothesis that a higher level of Cu, Zn SOD activity in RBC can be an early diagnostic peripheral marker of this disease and a sensor to monitor treatments with copper-chelating drugs.

Original language	English
Pages (from-to)	137-140
Number of pages	4
Journal	Neuroscience Letters
Volume	329
Issue number	2
DOIs	https://doi.org/10.1016/S0304-3940(02)00599-2
Publication status	Published - Aug 30 2002

Keywords

Alzheimer's disease
Apolipoprotein E
Copper
Copper, zinc superoxide dismutase
D-penicillamine

ASJC Scopus subject areas

Neuroscience(all)

Access to Document

10.1016/S0304-3940(02)00599-2

Fingerprint Dive into the research topics of 'Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine'. Together they form a unique fingerprint.

Cite this

Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. / Rossi, Luisa; Squitti, Rosanna; Pasqualetti, Patrizio; Marchese, Eliana; Cassetta, Emanuele; Forastiere, Elisabetta; Rotilio, Giuseppe; Rossini, Paolo M.; Finazzi-Agró, Alessandro.

In: Neuroscience Letters, Vol. 329, No. 2, 30.08.2002, p. 137-140.

Research output: Contribution to journal › Article › peer-review

Rossi, Luisa ; Squitti, Rosanna ; Pasqualetti, Patrizio ; Marchese, Eliana ; Cassetta, Emanuele ; Forastiere, Elisabetta ; Rotilio, Giuseppe ; Rossini, Paolo M. ; Finazzi-Agró, Alessandro. / Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. In: Neuroscience Letters. 2002 ; Vol. 329, No. 2. pp. 137-140.

@article{782dc355ad2649288ef2dc77345fb782,

title = "Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine",

abstract = "Copper, zinc superoxide dismutase (Cu, Zn SOD) activity was measured in red blood cells (RBC) of 32 patients affected by Alzheimer's disease (AD), eight other AD patients treated with the copper-chelating agent D-penicillamine, 13 first-degree relatives and 22 controls. All AD patients enrolled in our study showed a higher level of Cu, Zn SOD activity early in the disease. No correlation between apolipoprotein E genotype and SOD activity was found in AD patients. D-penicillamine treatment of AD patients for 24 weeks lowered the enzyme activity even below the control value. These results support the hypothesis that a higher level of Cu, Zn SOD activity in RBC can be an early diagnostic peripheral marker of this disease and a sensor to monitor treatments with copper-chelating drugs.",

keywords = "Alzheimer's disease, Apolipoprotein E, Copper, Copper, zinc superoxide dismutase, D-penicillamine",

author = "Luisa Rossi and Rosanna Squitti and Patrizio Pasqualetti and Eliana Marchese and Emanuele Cassetta and Elisabetta Forastiere and Giuseppe Rotilio and Rossini, {Paolo M.} and Alessandro Finazzi-Agr{\'o}",

year = "2002",

month = aug,

day = "30",

doi = "10.1016/S0304-3940(02)00599-2",

language = "English",

volume = "329",

pages = "137--140",

journal = "Neuroscience Letters",

issn = "0304-3940",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine

AU - Rossi, Luisa

AU - Squitti, Rosanna

AU - Pasqualetti, Patrizio

AU - Marchese, Eliana

AU - Cassetta, Emanuele

AU - Forastiere, Elisabetta

AU - Rotilio, Giuseppe

AU - Rossini, Paolo M.

AU - Finazzi-Agró, Alessandro

PY - 2002/8/30

Y1 - 2002/8/30

N2 - Copper, zinc superoxide dismutase (Cu, Zn SOD) activity was measured in red blood cells (RBC) of 32 patients affected by Alzheimer's disease (AD), eight other AD patients treated with the copper-chelating agent D-penicillamine, 13 first-degree relatives and 22 controls. All AD patients enrolled in our study showed a higher level of Cu, Zn SOD activity early in the disease. No correlation between apolipoprotein E genotype and SOD activity was found in AD patients. D-penicillamine treatment of AD patients for 24 weeks lowered the enzyme activity even below the control value. These results support the hypothesis that a higher level of Cu, Zn SOD activity in RBC can be an early diagnostic peripheral marker of this disease and a sensor to monitor treatments with copper-chelating drugs.

AB - Copper, zinc superoxide dismutase (Cu, Zn SOD) activity was measured in red blood cells (RBC) of 32 patients affected by Alzheimer's disease (AD), eight other AD patients treated with the copper-chelating agent D-penicillamine, 13 first-degree relatives and 22 controls. All AD patients enrolled in our study showed a higher level of Cu, Zn SOD activity early in the disease. No correlation between apolipoprotein E genotype and SOD activity was found in AD patients. D-penicillamine treatment of AD patients for 24 weeks lowered the enzyme activity even below the control value. These results support the hypothesis that a higher level of Cu, Zn SOD activity in RBC can be an early diagnostic peripheral marker of this disease and a sensor to monitor treatments with copper-chelating drugs.

KW - Alzheimer's disease

KW - Apolipoprotein E

KW - Copper

KW - Copper, zinc superoxide dismutase

KW - D-penicillamine

UR - http://www.scopus.com/inward/record.url?scp=0037199654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037199654&partnerID=8YFLogxK

U2 - 10.1016/S0304-3940(02)00599-2

DO - 10.1016/S0304-3940(02)00599-2

M3 - Article

C2 - 12165396

AN - SCOPUS:0037199654

VL - 329

SP - 137

EP - 140

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -